发布求助
文献互助 智能选刊 最新文献

Cancer Cell最新文献

筛选
英文 中文
Artificial intelligence 人工智能
IF 50.3 1区 医学
Cancer Cell Pub Date : 2024-06-10 DOI: 10.1016/j.ccell.2024.05.021
Moritz Gerstung, David Liu, Marzyeh Ghassemi, James Zou, Diego Chowell, Jonas Teuwen, Faisal Mahmood, Jakob Nikolas Kather
{"title":"Artificial intelligence","authors":"Moritz Gerstung, David Liu, Marzyeh Ghassemi, James Zou, Diego Chowell, Jonas Teuwen, Faisal Mahmood, Jakob Nikolas Kather","doi":"10.1016/j.ccell.2024.05.021","DOIUrl":"https://doi.org/10.1016/j.ccell.2024.05.021","url":null,"abstract":"<p>Experts discuss the challenges and opportunities of using artificial intelligence (AI) to study the evolution of cancer cells and their microenvironment, improve diagnosis, predict treatment response, and ensure responsible implementation in the clinic.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"27 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue 寻找甜蜜点：靶向肿瘤中的 RAS，同时保护正常组织
IF 50.3 1区 医学
Cancer Cell Pub Date : 2024-06-10 DOI: 10.1016/j.ccell.2024.05.020
Naiara Perurena, Karen Cichowski
{"title":"Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue","authors":"Naiara Perurena, Karen Cichowski","doi":"10.1016/j.ccell.2024.05.020","DOIUrl":"https://doi.org/10.1016/j.ccell.2024.05.020","url":null,"abstract":"<p>The development of mutant-selective KRAS inhibitors represents a major therapeutic advance; however, patients can develop resistance through feedback mechanisms and genetic alterations in the RAS pathway. Three publications in <em>Nature</em> and <em>Cancer Discovery</em> describe a promising RAS(ON) multi-selective inhibitor that simultaneously targets oncogenic RAS and multiple potential resistance mechanisms while sparing normal tissue.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"33 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mapping myeloid cell function: Spatial diversity in tumor and neuronal microenvironment 绘制髓系细胞功能图：肿瘤和神经元微环境的空间多样性
IF 50.3 1区 医学
Cancer Cell Pub Date : 2024-06-10 DOI: 10.1016/j.ccell.2024.05.018
Giulia Villa, Daniel Delev, Dieter Henrik Heiland
{"title":"Mapping myeloid cell function: Spatial diversity in tumor and neuronal microenvironment","authors":"Giulia Villa, Daniel Delev, Dieter Henrik Heiland","doi":"10.1016/j.ccell.2024.05.018","DOIUrl":"https://doi.org/10.1016/j.ccell.2024.05.018","url":null,"abstract":"<p>In this issue of <em>Cancer Cell</em>, Zhong et al. explore the dual role of TREM2 in glioblastoma-associated myeloid cells, demonstrating its function in promoting inflammation at the tumor-neural interface and suppression within the tumor core, influenced by the local microenvironment. These findings open up promising prospects for advancements in neuro-oncological immunotherapy.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"8 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The temporal progression of lung immune remodeling during breast cancer metastasis. 乳腺癌转移过程中肺部免疫重塑的时间进程
IF 48.8 1区 医学
Cancer Cell Pub Date : 2024-06-10 Epub Date: 2024-05-30 DOI: 10.1016/j.ccell.2024.05.004
Christopher S McGinnis, Zhuang Miao, Daphne Superville, Winnie Yao, Andrei Goga, Nathan E Reticker-Flynn, Juliane Winkler, Ansuman T Satpathy
{"title":"The temporal progression of lung immune remodeling during breast cancer metastasis.","authors":"Christopher S McGinnis, Zhuang Miao, Daphne Superville, Winnie Yao, Andrei Goga, Nathan E Reticker-Flynn, Juliane Winkler, Ansuman T Satpathy","doi":"10.1016/j.ccell.2024.05.004","DOIUrl":"10.1016/j.ccell.2024.05.004","url":null,"abstract":"<p><p>Tumor metastasis requires systemic remodeling of distant organ microenvironments that impacts immune cell phenotypes, population structure, and intercellular communication. However, our understanding of immune phenotypic dynamics in the metastatic niche remains incomplete. Here, we longitudinally assayed lung immune transcriptional profiles in the polyomavirus middle T antigen (PyMT) and 4T1 metastatic breast cancer models from primary tumorigenesis, through pre-metastatic niche formation, to the final stages of metastatic outgrowth at single-cell resolution. Computational analyses of these data revealed a TLR-NFκB inflammatory program enacted by both peripherally derived and tissue-resident myeloid cells that correlated with pre-metastatic niche formation and mirrored CD14<sup>+</sup> \"activated\" myeloid cells in the primary tumor. Moreover, we observed that primary tumor and metastatic niche natural killer (NK) cells are differentially regulated in mice and human patient samples, with the metastatic niche featuring elevated cytotoxic NK cell proportions. Finally, we identified cell-type-specific dynamic regulation of IGF1 and CCL6 signaling during metastatic progression that represents anti-metastatic immunotherapy candidate pathways.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":" ","pages":"1018-1031.e6"},"PeriodicalIF":48.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11255555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141183924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation T 淋巴细胞淋巴瘤细胞表达高水平的 BCL2、S1P1 和 ICAM1，导致肿瘤细胞内侵受阻
IF 50.3 1区 医学
Cancer Cell Pub Date : 2024-06-10 DOI: 10.1016/j.ccell.2024.05.019
Hui Feng, David L. Stachura, Richard M. White, Alejandro Gutierrez, Lu Zhang, Takaomi Sanda, Cicely A. Jette, Joseph R. Testa, Donna S. Neuberg, David M. Langenau, Jeffery L. Kutok, Leonard I. Zon, David Traver, Mark D. Fleming, John P. Kanki, A. Thomas Look
{"title":"T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation","authors":"Hui Feng, David L. Stachura, Richard M. White, Alejandro Gutierrez, Lu Zhang, Takaomi Sanda, Cicely A. Jette, Joseph R. Testa, Donna S. Neuberg, David M. Langenau, Jeffery L. Kutok, Leonard I. Zon, David Traver, Mark D. Fleming, John P. Kanki, A. Thomas Look","doi":"10.1016/j.ccell.2024.05.019","DOIUrl":"https://doi.org/10.1016/j.ccell.2024.05.019","url":null,"abstract":"No Abstract","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"26 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hand in hand to successful immunotherapy: CD8+ T cells and M1-like macrophages swap the baton 牵手成功的免疫疗法：CD8+ T 细胞和 M1 样巨噬细胞互换指挥棒
IF 50.3 1区 医学
Cancer Cell Pub Date : 2024-06-10 DOI: 10.1016/j.ccell.2024.05.012
Abir Hussein, Slava Stamova, Maria Xydia, Philipp Beckhove
{"title":"Hand in hand to successful immunotherapy: CD8+ T cells and M1-like macrophages swap the baton","authors":"Abir Hussein, Slava Stamova, Maria Xydia, Philipp Beckhove","doi":"10.1016/j.ccell.2024.05.012","DOIUrl":"https://doi.org/10.1016/j.ccell.2024.05.012","url":null,"abstract":"<p>Cancer immunotherapy is a pillar of clinical oncology but only achieves long-term remissions in a minority of cases. In this issue, van Elsas et al. show that effective immunotherapy requires a series of processes orchestrated by CD8<sup>+</sup> T cells that result in the recruitment and local activation of M1-like macrophages.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"29 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy 阻断肿瘤内CD8+ T细胞：Treg串扰可提高PD-1免疫疗法的疗效
IF 50.3 1区 医学
Cancer Cell Pub Date : 2024-06-10 DOI: 10.1016/j.ccell.2024.05.013
Shannon N. Geels, Alexander Moshensky, Rachel S. Sousa, Claire Murat, Matias A. Bustos, Benjamin L. Walker, Rima Singh, Stacey N. Harbour, Giselle Gutierrez, Michael Hwang, Thorsten R. Mempel, Casey T. Weaver, Qing Nie, Dave S.B. Hoon, Anand K. Ganesan, Shivashankar Othy, Francesco Marangoni
{"title":"Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy","authors":"Shannon N. Geels, Alexander Moshensky, Rachel S. Sousa, Claire Murat, Matias A. Bustos, Benjamin L. Walker, Rima Singh, Stacey N. Harbour, Giselle Gutierrez, Michael Hwang, Thorsten R. Mempel, Casey T. Weaver, Qing Nie, Dave S.B. Hoon, Anand K. Ganesan, Shivashankar Othy, Francesco Marangoni","doi":"10.1016/j.ccell.2024.05.013","DOIUrl":"https://doi.org/10.1016/j.ccell.2024.05.013","url":null,"abstract":"<p>PD-1 blockade unleashes potent antitumor activity in CD8<sup>+</sup> T cells but can also promote immunosuppressive T regulatory (Treg) cells, which may worsen the response to immunotherapy. Tumor-Treg inhibition is a promising strategy to improve the efficacy of checkpoint blockade immunotherapy; however, our understanding of the mechanisms supporting tumor-Tregs during PD-1 immunotherapy is incomplete. Here, we show that PD-1 blockade increases tumor-Tregs in mouse models of melanoma and metastatic melanoma patients. Mechanistically, Treg accumulation is not caused by Treg-intrinsic inhibition of PD-1 signaling but depends on an indirect effect of activated CD8<sup>+</sup> T cells. CD8<sup>+</sup> T cells produce IL-2 and colocalize with Tregs in mouse and human melanomas. IL-2 upregulates the anti-apoptotic protein ICOS on tumor-Tregs, promoting their accumulation. Inhibition of ICOS signaling before PD-1 immunotherapy improves control over immunogenic melanoma. Thus, interrupting the intratumor CD8<sup>+</sup> T cell:Treg crosstalk represents a strategy to enhance the therapeutic efficacy of PD-1 immunotherapy.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"70 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrated single cell analysis reveals co-evolution of malignant B cells and tumor micro-environment in transformed follicular lymphoma 综合单细胞分析揭示了转化型滤泡淋巴瘤中恶性 B 细胞和肿瘤微环境的共同进化过程
IF 50.3 1区 医学
Cancer Cell Pub Date : 2024-06-10 DOI: 10.1016/j.ccell.2024.05.011
Clémentine Sarkozy, Shaocheng Wu, Katsuyoshi Takata, Tomohiro Aoki, Susana B. Neriah, Katy Milne, Talia Goodyear, Celia Strong, Tashi Rastogi, Laura K. Hilton, Daniel Lai, Laurie H. Sehn, Pedro Farinha, Brad H. Nelson, Andrew Weng, Marco Marra, David W. Scott, Jeffrey W. Craig, Christian Steidl, Andrew Roth
{"title":"Integrated single cell analysis reveals co-evolution of malignant B cells and tumor micro-environment in transformed follicular lymphoma","authors":"Clémentine Sarkozy, Shaocheng Wu, Katsuyoshi Takata, Tomohiro Aoki, Susana B. Neriah, Katy Milne, Talia Goodyear, Celia Strong, Tashi Rastogi, Laura K. Hilton, Daniel Lai, Laurie H. Sehn, Pedro Farinha, Brad H. Nelson, Andrew Weng, Marco Marra, David W. Scott, Jeffrey W. Craig, Christian Steidl, Andrew Roth","doi":"10.1016/j.ccell.2024.05.011","DOIUrl":"https://doi.org/10.1016/j.ccell.2024.05.011","url":null,"abstract":"<p>Histological transformation of follicular lymphoma (FL) to aggressive forms is associated with poor outcome. Phenotypic consequences of this evolution and its impact on the tumor microenvironment (TME) remain unknown. We perform single-cell whole genome sequencing (scWGS) and transcriptome sequencing (scWTS) of 11 paired pre/post-transformation patient samples and scWTS of additional samples from patients without transformation. Our analysis reveals evolutionary dynamics of transformation at single-cell resolution, highlighting a shifting TME landscape, with an emerging immune-cell exhaustion signature, co-evolving with the shifting malignant B phenotype in a regulatory ecosystem. Integration of scWGS and scWTS identifies malignant cell pathways upregulated during clonal tumor evolution. Using multi-color immunofluorescence, we transfer these findings to a TME-based transformation biomarker, subsequently validated in two independent pretreatment cohorts. Taken together, our results provide a comprehensive view of the combined genomic and phenotypic evolution of malignant cells during transformation and shifting crosstalk between malignant cells and the TME.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"83 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Testing dilemmas in the clinic: Lessons learned from biomarker-based drug development 临床试验困境：从基于生物标记的药物开发中汲取的经验教训
IF 50.3 1区 医学
Cancer Cell Pub Date : 2024-06-10 DOI: 10.1016/j.ccell.2024.05.014
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Olga Kholmanskikh Van Criekingen, Simone Koole, David M. Thomas, Hans Gelderblom
{"title":"Testing dilemmas in the clinic: Lessons learned from biomarker-based drug development","authors":"Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Olga Kholmanskikh Van Criekingen, Simone Koole, David M. Thomas, Hans Gelderblom","doi":"10.1016/j.ccell.2024.05.014","DOIUrl":"https://doi.org/10.1016/j.ccell.2024.05.014","url":null,"abstract":"<p>Various tests based on different biomarkers have been developed to identify the best candidates for poly(ADP-ribose) polymerase (PARP)-inhibitor therapy. However, due to the absence of harmonization regarding these complex biomarkers, along with various cutoff points and unknown spatial and temporal variations, it is difficult to define the clinical utility of each test and ensure uniformity in treatment decision-making. Here, we propose measures to align biomarker definitions and minimum analytical performance characteristics for diagnostics to ensure equitable and sustainable access to precision medicine.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"53 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Let it be: Preserving tumor-draining lymph nodes in the era of immuno-oncology 顺其自然：在免疫肿瘤学时代保留肿瘤引流淋巴结
IF 50.3 1区 医学
Cancer Cell Pub Date : 2024-06-10 DOI: 10.1016/j.ccell.2024.05.015
Robert Saddawi-Konefka, Shiruyeh Schokrpur, J. Silvio Gutkind
{"title":"Let it be: Preserving tumor-draining lymph nodes in the era of immuno-oncology","authors":"Robert Saddawi-Konefka, Shiruyeh Schokrpur, J. Silvio Gutkind","doi":"10.1016/j.ccell.2024.05.015","DOIUrl":"https://doi.org/10.1016/j.ccell.2024.05.015","url":null,"abstract":"<p>Solid cancers often progress via metastasis to lymph nodes. Consequently, lymphadenectomy is central to stage cancers and eradicates disease spread. However, mounting evidence suggests that cancer immunotherapies drive antitumor immune responses within lymph nodes. This implies that immunotherapy, delivered with standard oncologic therapies, may require specific treatment sequencing to initiate immunosurveillance and affect primary tumor responses. As supported by recent preclinical and clinical studies, lymphatic-preserving strategies may offer the best promise for driving the next generation of breakthrough immunotherapy approaches.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"6 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信